Vericel Corp Ord (VCEL) - Total Liabilities
Based on the latest financial reports, Vericel Corp Ord (VCEL) has total liabilities worth $133.33 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vericel Corp Ord - Total Liabilities Trend (1995–2025)
This chart illustrates how Vericel Corp Ord's total liabilities have evolved over time, based on quarterly financial data. See Vericel Corp Ord current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Vericel Corp Ord Competitors by Total Liabilities
The table below lists competitors of Vericel Corp Ord ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Interface Inc
NASDAQ:TILE
|
USA | $571.20 Million |
|
Liberty Global PLC Class C
NASDAQ:LBTYK
|
USA | $12.43 Billion |
|
NEXA RESOURCES S.A. DL 1
F:NE0
|
Germany | €3.99 Billion |
|
Believe SAS
PA:BLV
|
France | €811.38 Million |
|
Deterra Royalties Ltd
AU:DRR
|
Australia | AU$236.22 Million |
|
Jiangxi Hongcheng Waterworks Co Ltd
SHG:600461
|
China | CN¥14.11 Billion |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
USA | $150.22 Million |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥2.16 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Vericel Corp Ord's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vericel Corp Ord (VCEL) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vericel Corp Ord's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vericel Corp Ord (1995–2025)
The table below shows the annual total liabilities of Vericel Corp Ord from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $133.33 Million | -5.28% |
| 2024-12-31 | $140.75 Million | +10.22% |
| 2023-12-31 | $127.70 Million | +58.19% |
| 2022-12-31 | $80.73 Million | +10.22% |
| 2021-12-31 | $73.24 Million | +2.66% |
| 2020-12-31 | $71.35 Million | +69.28% |
| 2019-12-31 | $42.15 Million | +156.09% |
| 2018-12-31 | $16.46 Million | -48.63% |
| 2017-12-31 | $32.04 Million | +34.11% |
| 2016-12-31 | $23.89 Million | +96.15% |
| 2015-12-31 | $12.18 Million | +2.02% |
| 2014-12-31 | $11.94 Million | +124.36% |
| 2013-12-31 | $5.32 Million | -6.07% |
| 2012-12-31 | $5.67 Million | -72.65% |
| 2011-12-31 | $20.71 Million | -30.75% |
| 2010-12-31 | $29.91 Million | +1401.26% |
| 2009-12-31 | $1.99 Million | -30.91% |
| 2008-12-31 | $2.88 Million | -37.29% |
| 2007-12-31 | $4.60 Million | +81.06% |
| 2006-12-31 | $2.54 Million | +192.17% |
| 2005-12-31 | $869.00K | +55.73% |
| 2004-12-31 | $558.00K | -3.79% |
| 2003-12-31 | $580.00K | -22.67% |
| 2002-12-31 | $750.00K | -25.82% |
| 2001-12-31 | $1.01 Million | +0.90% |
| 2000-12-31 | $1.00 Million | -2.62% |
| 1999-12-31 | $1.03 Million | -32.66% |
| 1998-12-31 | $1.53 Million | -27.17% |
| 1997-12-31 | $2.10 Million | +16.56% |
| 1996-12-31 | $1.80 Million | +38.46% |
| 1995-12-31 | $1.30 Million | -- |
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more